Cirrhosis News and Research

Latest Cirrhosis News and Research

Portal vein hypertension diminishes after hepatitis C recovery

This inflammatory viral infection of the liver causes inflexible scar tissue to form. This in turn impedes blood flow through the organ, with resulting hypertension in the portal vein.

15 Jun 2016

New RNA aptamer can prevent pathogenic protein misfolding

Several diseases occur when mutations cause misfolding of proteins. These include "serpinopathies" which is a group of rare heritable diseases. They are caused by mutations of so-called "serpin" inhibitors of proteolytic enzymes involved in blood coagulation, tissue remodeling, and other important physiological functions.

10 Jun 2016

Novel enzyme immunoassay helps diagnose HCV infection in one simple step

The current standard in diagnosing Hepatitis C virus (HCV) infection requires two sequential steps that make it suboptimal, costly, inconvenient, time consuming, and globally not widely available or affordable.

8 Jun 2016

Scientists use new technique to repair fibrotic liver cells within the organ

Advances in stem cell research have made it possible to convert patients' skin cells into heart cells, kidney cells, liver cells and more in the lab dish, giving researchers hope that one day such cells could replace organ transplantation for patients with organ failure.

3 Jun 2016

Ocaliva drug gets FDA approval for primary biliary cholangitis treatment

On Friday, May 27, the U.S. Food and Drug Administration granted accelerated approval for Ocaliva (obeticholic acid) for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as a single therapy in adults unable to tolerate UDCA.

1 Jun 2016

Portable breath sensor to detect lifestyle diseases? An interview with Osamu Tsuboi, Fujitsu Laboratories

Generally, it is thought that there is a connection between concentrations of ammonia and liver disease, such as fatty liver and cirrhosis, Helicobacter pylori (H. pylori) infection, and kidney failure.

31 May 2016

Even light or non-drinkers who become easily inebriated may develop fatty liver disease

People who have reduced enzyme activity to breakdown active aldehyde, i.e., those who become easily inebriated, are more likely to develop fatty liver disease even if they do not drink alcohol.

25 May 2016

Epigenetic modification of Igfbp2 gene may increase risk of obesity and fatty liver

Scientists of the German Center for Diabetes Research led by the German Institute of Human Nutrition have shown in a mouse model that the epigenetic modification of the Igfbp2 gene observed in the young animal precedes a fatty liver in the adult animal later in life.

24 May 2016

High levels of secretin hormone may play vital role in management of chronic liver diseases

High levels of a digestive hormone called secretin may play an important role in the management of certain chronic liver diseases, according to new research published in the journal Hepatology. These findings could result in new ways to treat cholestatic liver diseases, a condition that impairs the movement of bile, the fluid produced by the liver to digest fats.

18 May 2016

Clinical study shows sitagliptin drug not effective in treating NAFLD

A diabetes medication described in some studies as an effective treatment for nonalcoholic fatty liver disease (NAFLD) works no better than a placebo, report researchers at University of California San Diego School of Medicine, after conducting the first randomized, double-blind, controlled clinical trial of sitagliptin, an oral antihyperglycemic marketed by Merck & Co. under the name Januvia.

13 May 2016

New study sheds more light on level of alcohol consumption among people with hepatitis C

Drinking alcohol can increase the risk of illness and death from the hepatitis C virus. A new national household study of U.S. adults published in the American Journal of Preventive Medicine shows that many people living with hepatitis C report either former or current excessive alcohol use.

11 May 2016

High-level quantum chemical computations help unravel underlying mechanism of hepatocellular toxicity

Balasubramanian and Basak have recently reported quantum chemical computations that enhance our understanding of mechanisms for the causes of liver toxicity. Hepatocellular carcinoma is one of the most common forms of cancer, and the primary cause has been attributed to liver fibrosis by chemical toxins, which is followed by liver cirrhosis.

9 May 2016

Antiviral therapies equal survival rate of HCV-related cirrhosis patients with general population

The survival rate of patients with hepatitis C virus-related cirrhosis who respond well to antiviral therapies equals that of the general population, say investigators in the Journal of Hepatology.

5 May 2016

WFA+-M2BP levels linked to liver fibrosis, HCC progression in chronic HBV

Japanese researchers have found that serum levels of glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein are a useful marker of not only the degree of liver fibrosis, but also progression to hepatocellular carcinoma in patients with chronic hepatitis B virus infection.

27 Apr 2016

Serum marker may flag liver fibrosis in chronic HBV

Serum levels of Wisteria floribunda agglutinin-positive Mac-2-binding protein may reflect the severity of liver fibrosis in patients with chronic hepatitis B virus infection, say researchers.

27 Apr 2016

Regular aspirin use may help reduce risk of bile duct cancer

Regular use of aspirin was linked with a significantly reduced risk of developing bile duct cancer, also called cholangiocarcinoma, in a recent study. The findings, which are published in the journal Hepatology, indicate that additional research on the potential of aspirin for preventing bile duct cancer is warranted.

27 Apr 2016

Acute liver failure after massive hepatectomy improves with liver cell transplantation

Liver failure often occurs after an extensive hepatectomy, which is the surgical resection of the liver. While liver cell transplantation is a useful therapy for acute liver failure after massive hepatectomy, when cells are transplanted through liver portal veins raises the risk of embolization, such as the formation and movement of a blood clot, often with fatal consequences.

26 Apr 2016

New therapy strategy for liver disease shows initial measureable success with norUrso

The new therapy strategy for primary sclerosing cholangitis, a liver disease that at present still cannot be cured with medication, shows initial measureable success with the nor-ursodeoxycholic acid (norUrso).

19 Apr 2016

VIEKIRAX and EXVIERA achieve high SVR rates in GT1 and GT4 hepatitis C virus infected patients

AbbVie, a global biopharmaceutical company, today announced new real-world data showing 96 percent of genotype 1 (GT1) patients (n=486/505 assessable for analysis) and 100 percent (n=53/53) of genotype 4 (GT4) patients achieved sustained virologic response at 12 weeks post-treatment (SVR12).

15 Apr 2016

Patients with genotype 1 chronic HCV infection achieve high SVR rates with VIEKIRAX + EXVIERA

AbbVie, a global biopharmaceutical company, today announced data showing that patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection who received the recommended regimen of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets), with or without ribavirin (RBV), achieved high sustained virologic response rates at 48 weeks post-treatment (SVR48), regardless of the presence of baseline resistance-associated variants (RAVs).

15 Apr 2016

Cirrhosis News and Research

Latest Cirrhosis News and Research

Portal vein hypertension diminishes after hepatitis C recovery

New RNA aptamer can prevent pathogenic protein misfolding

Novel enzyme immunoassay helps diagnose HCV infection in one simple step

Scientists use new technique to repair fibrotic liver cells within the organ

Ocaliva drug gets FDA approval for primary biliary cholangitis treatment

Portable breath sensor to detect lifestyle diseases? An interview with Osamu Tsuboi, Fujitsu Laboratories

Even light or non-drinkers who become easily inebriated may develop fatty liver disease

Epigenetic modification of Igfbp2 gene may increase risk of obesity and fatty liver

High levels of secretin hormone may play vital role in management of chronic liver diseases

Clinical study shows sitagliptin drug not effective in treating NAFLD

New study sheds more light on level of alcohol consumption among people with hepatitis C

High-level quantum chemical computations help unravel underlying mechanism of hepatocellular toxicity

Antiviral therapies equal survival rate of HCV-related cirrhosis patients with general population

WFA+-M2BP levels linked to liver fibrosis, HCC progression in chronic HBV

Serum marker may flag liver fibrosis in chronic HBV

Regular aspirin use may help reduce risk of bile duct cancer

Acute liver failure after massive hepatectomy improves with liver cell transplantation

New therapy strategy for liver disease shows initial measureable success with norUrso

VIEKIRAX and EXVIERA achieve high SVR rates in GT1 and GT4 hepatitis C virus infected patients

Patients with genotype 1 chronic HCV infection achieve high SVR rates with VIEKIRAX + EXVIERA

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Cirrhosis News and Research

Latest Cirrhosis News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in